On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies

Recent Patents on CNS Drug Discovery

Volumn 5, Issue 3, 2010, Pages 239-252

  Sarin, Hemant ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Acid labile covalent bond; Blood brain barrier; Blood CNS barrier; Dendrimer nanoparticle; Diaphragmed fenestrae; Endothelial glycocalyx layer; Malignant glioma; Neutron capture therapy; Physiologic upper limit of pore size; Solid cancer; Theranostic agent

Indexed keywords

DENDRIMER; DOXORUBICIN; FERRITIN; GADOLINIUM; LOMUSTINE; NANOPARTICLE; PROPOFOL; RHODAMINE B; SMALL MOLECULE TRANSPORT AGENT; VASCULOTROPIN;

ARTICLE; BLOOD VESSEL PERMEABILITY; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CAPILLARY BLOOD; CAPILLARY WALL; CENTRAL NERVOUS SYSTEM TUMOR; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; EXTRACELLULAR SPACE; EXTRAVASATION; FLOW RATE; GLIOBLASTOMA; HUMAN; HYDRODYNAMICS; INTERSTITIUM; LIPID STORAGE; MACROMOLECULE; NERVE DEGENERATION; PARTICLE SIZE; PLASMA VOLUME; PRIORITY JOURNAL; SPINAL CORD; SYSTEMIC CIRCULATION; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; CENTRAL NERVOUS SYSTEM NEOPLASMS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MOLECULAR CONFORMATION; NANOTECHNOLOGY; PARTICLE SIZE; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 78649356144     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488910793362403     Document Type: Article

References (142)

1. Sarin H, Kanevsky A, Wu H, Brimacombe K, Fung S, Sousa A, et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med 2008; 6(80). [Online]
2. Sarin H. Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J Transl Med 2009; 7(77). [Online]
3. Sarin H. Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors. Ther Deliv 2010; 1(2).
4. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 2003; 10(6): 463-70.
5. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007; 28(7): 977-86.
6. Ay I, Francis JW, Brown Jr RH. VEGF increases blood-brain barrier permeability to Evans blue dye and tetanus toxin fragment C but not adeno-associated virus in ALS mice. Brain Res 2008; 1234: 198-205.
7. Petito CK, Cash KS. Blood-brain barrier abnormalities in acquired immunodeficiency syndrome: Immunohistochemical localization of serum proteins in postmortem brain. Ann Neurol 1992; 32(5): 658-66.
8. Pai MP, Sakoglu U, Peterson SL, Lyons CR, Sood R. Characterization of BBB permeability in a preclinical model of cryptococcal meningoencephalitis using magnetic resonance imaging. J Cereb Blood Flow Metab 2008; 29(3): 545-53.
9. Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 2003; 2003; 9(6): 540-9.
10. Fabis MJ, Scott GS, Kean RB, Koprowski H, Hooper DC. Loss of blood-brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models. Proc Nat Acad Sci USA 2007; 104(13): 5656-61.
11. Hawkins CP, Munro PM, MacKenzie F, Kesselring J, Tofts PS, du Boulay EP, et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 1990; 113(Pt 2): 365-78.
12. Proescholdt MA, Jacobson S, Tresser N, Oldfield EH, Merrill MJ. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 2002; 61(10): 914-25.
13. Zlokovic BV, Skundric DS, Segal MB, Colover J, Jankov RM, Pejnovic N, et al. Blood-brain barrier permeability changes during acute allergic encephalomyelitis induced in the guinea pig. Metab Brain Dis 1989; 4(1): 33-40.
14. Larsson HBW, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med 1990; 16(1): 117.
15. Pluta R. Pathological opening of the blood-brain barrier to horseradish peroxidase and amyloid precursor protein following ischemia-reperfusion brain injury. Chemotherapy 2005; 51(4): 223-6.
16. Pluta R, Ułamek M, Januszewski S. Micro-blood-brain barrier openings and cytotoxic fragments of amyloid precursor protein accumulation in white matter after ischemic brain injury in long-lived rats. Brain Edema XIII 2006: 267-71.
17. Clatterbuck RE, Eberhart CG, Crain BJ, Rigamonti D. Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformations. J Neurol Neurosurg Psychiatry 2001; 71(2): 188-92.
18. Cohen DM, Patel CB, Ahobila-Vajjula P, Sundberg LM, Chacko T, Liu SJ, et al. Blood-spinal cord barrier permeability in experimental spinal cord injury: Dynamic contrast-enhanced MRI. NMR Biomed 2009; 22(3): 332-41.
19. Nag S, Takahashi JL, Kilty DW. Role of vascular endothelial growth factor in blood-brain barrier breakdown and angiogenesis in brain trauma. J Neuropathol Exp Neurol 1997; 56(8): 912-21.
20. Noble LJ, Wrathall JR. Distribution and time course of protein extravasation in the rat spinal cord after contusive injury. Brain Res 1989; 482(1): 57-66.
21. Dar, M. Methods for the treatment of central nervous system tumors. US20090005398 (2009).
22. Chou, F.-I. Pharmaceutical composition for boron neutron capture therapy containing triphenylboroxin. US7094771 (2006).
23. Ekwuribe NN, Rhadakrishnan B, Price CH, Anderson Jr. W, Ansari AM. Enkephalin conjugates. US6956051 (2005).
24. Sarin H, Kanevsky AS, Fung SH, Butman JA, Cox RW, Glen D, et al. Metabolically stable bradykinin b2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J Transl Med 2009; 7(33). [Online]
25. Shi, X., Wang, S., Baker Jr, J.R. Dendrimer based compositions and methods of using the same. US20090053139 (2009).
26. Bonastre, R.A., Piqueras, M.M. Use of adenoviruses mutated in the va genes for cancer treatment. US7344711 (2008).
27. Pardridge, W.M. Non-invasive gene targeting to the brain. US6372250 (2002).
28. Pardridge, W.M. Immunonanoparticles. US20050042298 (2005).
29. Troy, C.M., Connolly, S.E., Prunell, F., Ducruet, A.F. Delivery of double-stranded RNA into the central nervous system. US20090280058 (2009).
30. Lamensdorf, I., Katzhendler, J. Amphiphylic peptide-PNA conjugates for the delivery of PNA through the blood brain barrier. US20060142227 (2006).
31. Sarin H, Kanevsky A, Wu H, Sousa A, Wilson C, Aronova M, et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med 2009; 7(51). [Online]
32. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998; 95: 4607-12.
33. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235(4787): 442-7.
34. Lane TE, Carson M, Bergmann C, Wyss-Coray T. Central Nervous System Diseases and Inflammation. Springer USA 2008.
35. Proescholdt MA, Heiss JD, Walbridge S, Muhlhauser J, Capogrossi MC, Oldfield EH, et al. Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J Neuropathol Exp Neurol 1999; 58(6): 613-27.
36. Majno G, Gilmore V, Leventhal M. On the mechanism of vascular leakage caused by histamine-type mediators. A microscopic study in vivo. Circ Res 1967; 21(6): 833-47.
37. Joris I, Majno G, Corey EJ, Lewis RA. The mechanism of vascular leakage induced by leukotriene e4. Endothelial contraction. Am J Pathol 1987; 126(1): 19.
38. Michel CC, Neal CR. Openings through endothelial cells associated with increased microvascular permeability. Microcirculation 1999; 6(1): 45-54.
39. Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1997; 57(4): 765-72.
40. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146(5): 1029-39.
41. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenesis Res 2010; 2(14): (Online).
42. Sarin H. Effective transvascular delivery of chemotherapy into cancer cells with imageable nanoparticles in the 7 to 10 nanometer size range. In: Slevin M, Ed. Current Advances in the Medical Application of Nanotechnology: eBentham Books (in press).
43. Soo Choi H, Liu W, Misra P, Tanaka E, Zimmer J, Itty Ipe B, et al. Renal clearance of quantum dots. Nat Biotechnol 2007; 25: 1165-70.
44. Kobayashi H, Kawamoto S, Jo SK, Bryant Jr HL, Brechbiel MW, Star RA. Macromolecular MRI contrast agents with small dendrimers: Pharmacokinetic differences between sizes and cores. Bioconjug Chem 2003; 14(2): 388-94.
45. Tomalia DA, Reyna LA, Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans 2007; 35(1): 61-7.
46. Lee CC, Gillies ER, Fox ME, Guillaudeu SJ, Frechet JMJ, Dy EE, et al. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci USA 2006; 103(45): 16649.
47. Baker JR, Jr. Dendrimer-based nanoparticles for cancer therapy. Hematology 2009; (1): 708-19.
48. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005; 65(12): 5317-24.
49. Weinbaum S, Zhang X, Han Y, Vink H, Cowin SC. Mechanotransduction and flow across the endothelial glycocalyx. Proc Natl Acad Sci USA 2003; 100: 7988-95.
50. Squire JM, Chew M, Nneji G, Neal C, Barry J, Michel C. Quasiperiodic substructure in the microvessel endothelial glycocalyx: A possible explanation for molecular filtering? J Struct Biol 2001; 136(3): 239-55.
51. Fraser R, Dobbs BR, Rogers GWT. Lipoproteins and the liver sieve: The role of the fenestrated sinusoidal endothelium in lipoprotein metabolism, atherosclerosis, and cirrhosis. Hepatology 1995; 21(3): 863-74.
52. Armstrong JK, Wenby RB, Meiselman HJ, Fisher TC. The hydrodynamic radii of macromolecules and their effect on red blood cell aggregation. Biophys J 2004; 87(6): 4259-70.
53. Hupfeld S, Hols, ter AM, Skar M, Frantzen CB, Brandl M. Liposome size analysis by dynamic/static light scattering upon size exclusion-/field flow-fractionation. J Nanosci Nanotechnol 2006; 6: 3025-31.
54. Chattopadhyay N, Zastre J, Wong H-L, Wu X, Bendayan R. Solid lipid nanoparticles enhance the delivery of the hiv protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res 2008; 25(10): 2262-71.
55. Reddy M, Wu L, Kou W, Ghorpade A, Labhasetwar V. Superoxide dismutase-loaded plga nanoparticles protect cultured human neurons under oxidative stress. Appl Biochem Biotechnol 2008; 151(2): 565-77.
56. Weinstein JS, Varallyay CG, Dosa E, Gahramanov S, Hamilton B, Rooney WD, et al. Superparamagnetic iron oxide nanoparticles: Diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 2010; 30(1): 15-35.
57. van Kasteren SI, Campbell SJ, Serres S, Anthony DC, Sibson NR, Davis BG. Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease. Proc Natl Acad Sci USA 2009; 106(1): 18-23.
58. Brechbiel, M.W., Bumb, A., Choyke, P., Fugger, L., Dobson, P.J. Multifunctional nanoparticles and compositions and methods of use thereof. US20100092384 (2010).
59. Rameshwer S, Thommey TP, Desai AM, Kotlyar A, Park SJ, Baker Jr JR. Her2 specific delivery of methotrexate by dendrimer conjugated anti-her2 mAb. Nanotechnology 2008; 19(29): 295102.
60. Gao X, Cui Y, Levenson RM, Chung LWK, Nie S. in vivo Cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004; 22(8): 969-76.
61. Dobrovolskaia MA, Patri AK, Zheng J, Clogston JD, Ayub N, Aggarwal P, et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomed Nanotechnol Biol Med 2009; 5(2): 106-17.
62. Prosa T, Bauer B, Amis E, Tomalia D, Scherrenberg R. A saxs study of the internal structure of dendritic polymer systems. J Polym Sci Part B Polym Phys 1997; 35: 2913-24.
63. Nisato G, Ivkov R, Amis E. Size invariance of polyelectrolyte dendrimers. Macromolecules 2000; 33: 4172-6.
64. Yordanov AT, Kobayashi H, English SJ, Reijnders K, Milenic D, Krishna MC, et al. Gadolinium-labeled dendrimers as biometric nanoprobes to detect vascular permeability. J Mater Chem 2003; 13(7): 1523-5.
65. Kobayashi H, Brechbiel MW. Dendrimer-based nanosized mri contrast agents. Curr Pharm Biotechnol 2004; 5(6): 539-49.
66. Venditto VJ, Regino CAS, Brechbiel MW. Pamam dendrimer based macromolecules as improved contrast agents. Mol Pharm 2005; 2(4): 302-11.
67. Brechbiel, M.W., Xu, H. Method of preparing macromolecular contrast agents and uses thereof. US20100056776 (2010).
68. Ogawa M, Regino CAS, Marcelino B, Williams M, Kosaka N, Bryant LH, et al. New nanosized biocompatible MR contrast agents based on lysine-dendri-graft macromolecules. Bioconjug Chem 2010; 21(5): 955-60.
69. Sousa AA, Aronova MA, Wu H, Sarin H, Griffiths GL, Leapman RD. Determining molecular mass distributions and compositions of functionalized dendrimer nanoparticles. Nanomedecine 2009; 4: 391-9.
70. Laurent S, Bridot J-L, Elst LV, Muller RN. Magnetic iron oxide nanoparticles for biomedical applications. Future Med Chem 2010; 2(3): 427-49.
71. Schroeter M, Saleh A, Wiedermann D, Hoehn M, Jander S. Histochemical detection of ultrasmall superparamagnetic iron oxide (uspio) contrast medium uptake in experimental brain ischemia. Magn Reson Med 2004; 52(2): 403-6.
72. Desestret V, Brisset J-C, Moucharrafie S, Devillard E, Nataf S, Honnorat J, et al. Early-stage investigations of ultrasmall superparamagnetic iron oxide-induced signal change after permanent middle cerebral artery occlusion in mice. Stroke 2009; 40(5): 1834-41.
73. Bridot JL, Dayde D, Riviere C, Mandon C, Billotey C, Lerondel S, et al. Hybrid gadolinium oxide nanoparticles combining imaging and therapy. J Mater Chem 2009; 19(16): 2328-35.
74. Bridot JL, Faure AC, Laurent S, Riviere C, Billotey C, Hiba B, et al. Hybrid gadolinium oxide nanoparticles: Multimodal contrast agents for in vivo imaging. J Am Chem Soc 2007; 129(16): 5076-84.
75. Faure AC, Dufort S, Josserand V, Perriat P, Coll JL, Roux S, et al. Control of the in vivo biodistribution of hybrid nanoparticles with different poly(ethylene glycol) coatings. Small 2009; 5(22): 2565-75.
76. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: A new X-ray contrast agent. Br J Radiol 2006; 79(939): 248-53.
77. Alric C, Taleb J, Le Duc G, Mandon C, Billotey C, Le Meur-Herland A, et al. Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging. J Am Chem Soc 2008; 130(18): 5908-15.
78. Alric C, Serduc R, Mandon C, Taleb J, Le Duc G, Le Meur-Herland A, et al. Gold nanoparticles designed for combining dual modality imaging and radiotherapy. Gold Bull 2008; 41(2): 90-7.
79. Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflügers Arch Eur J Physiol 2000; 440(5): 653-66.
80. Harrison PM. The structure of apoferritin: Molecular size, shape and symmetry from x-ray data. J Mol Biol 1963; 6(5): 404-22, IN3-IN9.
81. Dermietzel R, Thürauf N, Kalweit P. Surface charges associated with fenestrated brain capillaries: II. in vivo Studies on the role of molecular charge in endothelial permeability. J Ultrastruct Res 1983; 84(2): 111-19.
82. Peress NS, Tompkins D. Effect of molecular charge on choroidplexus permeability: Tracer studies with cationized ferritins. Cell Tissue Res 1981; 219(2): 425-31.
83. Triguero D, Buciak JB, Yang J, Pardridge WM. Blood-brain barrier transport of cationized immunoglobulin G: Enhanced delivery compared to native protein. Proc Natl Acad Sci USA 1989; 86(12): 4761-5.
84. Jeansson M, Bjorck K, Tenstad O, Haraldsson B. Adriamycin alters glomerular endothelium to induce proteinuria. J Am Soc Nephrol 2009; 20(1): 114-22.
85. Merrill MJ, Oldfield EH. A reassessment of vascular endothelial growth factor in central nervous system pathology. J Neurosurg 2005; 103(5): 853-68.
86. Roberts WG, Delaat J, Nagane M, Huang S, Cavenee WK, Palade GE. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol 1998; 153(4): 1239-48.
87. Bearer EL, Orci L, Sors P. Endothelial fenestral diaphragms: A quick-freeze, deep-etch study. J Cell Biol 1985; 100(2): 418-28.
88. Melamed S, Ben-Sira I, Ben-Shaul Y. Ultrastructure of fenestrations in endothelial choriocapillaries of the rabbit--a freeze-fracturing study. Br J Ophthalmol 1980; 64(7): 537-43.
89. Leblond CP, Inoue S. Structure, composition, and assembly of basement membrane. Am J Anat 1989; 185(4): 367-90.
90. Yurchenco PD, Schittny JC. Molecular architecture of basement membranes. FASEB J 1990; 4(6): 1577-90.
91. Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett SP, Potter H, et al. Evidence of compromised blood-spinal cord barrier in early and late symptomatic sod1 mice modeling als. PLoS ONE 2007; 2(11): e1205.
92. Shibata S. Ultrastructure of capillary walls in human brain tumors. Acta Neuropathol (Berl) 1989; 78(6): 561-71.
93. Hirata A, Baluk P, Fujiwara T, McDonald DM. Location of focal silver staining at endothelial gaps in inflamed venules examined by scanning electron microscopy. Am J Physiol Lung Cell Mol Physiol 1995; 269(3): L403-18.
94. Baluk P, Hirata A, Thurston G, Fujiwara T, Neal CR, Michel CC, et al. Endothelial gaps: Time course of formation and closure in inflamed venules of rats. Am J Physiol Lung Cell Mol Physiol 1997; 272(1): L155-70.
95. Cotran RS, Suter ER, Majno G. The use of colloidal carbon as a tracer for vascular injury. A review. Vasc Dis 1967; 4(2): 107-27.
96. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, Di Tomaso E, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA 2001; 98(8): 4628-33.
97. Dehouck M-P, Jolliet-Riant P, Brée F, Fruchart J-C, Cecchelli R, Tillement J-P. Drug transfer across the blood-brain barrier: Correlation between in vitro and in vivo models. J Neurochem 1992; 58(5): 1790-7.
98. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 1980; 23(6): 682-4.
99. Brightman MW. Morphology of blood-brain interfaces. Exp Eye Res 1977; 25(Suppl): 1-25.
100. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 1969; 40(3): 648-77.
101. Gross PM, Blasberg RG, Fenstermacher JD, Patlak CS. The microcirculation of rat circumventricular organs and pituitary gland. Brain Res Bull 1987; 18(1): 73-85.
102. Kamba T, Tam BYY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290(2): H560-76.
103. Bouldin TW, Krigman MR. Differential permeability of cerebral capillary and choroid plexus to lanthanum ion. Brain Res 1975; 99(2): 444-8.
104. Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967; 34(1): 207-17.
105. Sorensen SC. The permeability to small ions of tight junctions between cerebral endothelial cells. Brain Res 1974; 70(1): 174-8.
106. Fenstermacher JD, Johnson JA. Filtration and reflection coefficients of the rabbit blood-brain barrier. Am J Physiol 1966; 211(2): 341-6.
107. Schmidley JW, Wissig SL. Anionic sites on the luminal surface of fenestrated and continuous capillaries of the cns. Brain Res 1986; 363(2): 265-71.
108. Maharaj ASR, Walshe TE, Saint-Geniez M, Venkatesha S, Maldonado AE, Himes NC, et al. Vegf and tgf-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med 2008; 205(2): 491-501.
109. Groothuis DR, Fischer JM, Pasternak JF, Blasberg RG, Vick NA, Bigner DD. Regional measurements of blood-to-tissue transport in experimental rg-2 rat gliomas. Cancer Res 1983; 43(7): 3368-73.
110. Ferrier MC, Sarin H, Fung SH, Schatlo B, Pluta RM, Gupta SN, et al. Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia 2007; 9(7): 546-55.
111. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006; 98(5): 335-44.
112. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991; 17(2): 357-67.
113. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in cns gd-dtpa enhanced mr imaging. J Comput Assist Tomogr 1991; 15(4): 621.
114. Hesselink JR, Press GA. MR contrast enhancement of intracranial lesions with Gd-DTPA. Radiol Clin North Am 1988; 26(4): 873-87.
115. Lagarde M, Bernoud N, Brossard N, Lemaitre-Delaunay D, Thiès F, Croset M, et al. Lysophosphatidylcholine as a preferred carrier form of docosahexaenoic acid to the brain. J Mol Neurosci 2001; 16(2): 201-4.
116. Ravenelle F, Gori S, Le Garrec D, Lessard D, Luo L, Palusova D, et al. Novel lipid and preservative-free propofol formulation: Properties and pharmacodynamics. Pharm Res 2008; 25(2): 313-9.
117. Levin VA, Kabra P. Effectiveness of the nitrosoureas as a function of their lipid solubility in the chemotherapy of experimental rat brain tumors. Cancer Chemother Rep 1974; 58(6): 787.
118. Levin VA, Kabra PA, Freeman-Dove MA. Relationship of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) pharmacokinetics of uptake, distribution, and tissue/plasma partitioning in rat organs and intracerebral tumors. Cancer Chemother and Pharm 1978; 1(4): 233.
119. Rivera R, Antognini JF. Perioperative drug therapy in elderly patients. Anesthesiology 2009; 110(5): 1176-81.
120. Sekine I, Fukuda H, Kunitoh H, Saijo N. Cancer chemotherapy in the elderly. Jpn J Clin Oncol 1998; 28(8): 463-73.
121. Hurria A, Lichtman SM. Clinical pharmacology of cancer therapies in older adults. Br J Cancer 2008; 98(3): 517-22.
122. Sawada T, Kato Y, Sakayori N, Takekawa Y, Kobayashi M. Expression of the multidrug-resistance p-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors. Brain Tumor Pathol 1999; 16(1): 23-7.
123. Eilers M, Roy U, Mondal D. Mrp (abcc) transporters-mediated efflux of anti-hiv drugs, saquinavir and zidovudine, from human endothelial cells. Exp Biol Med 2008; 233(9): 1149-60.
124. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, et al. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 2009; 20(1): 175-81.
125. Greig NH, Soncrant TT, Shetty HU, Momma S, Smith QR, Rapoport SI. Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother Pharmacol 1990; 26(4): 263.
126. Provenzale JM, Silva GA. Uses of nanoparticles for central nervous system imaging and therapy. Am J Neuroradiol 2009; 30(7): 1293-301.
127. Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: From the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci 2009; 98(2): 411-29.
128. Kumar P, Wu H, McBride JL, Jung K-E, Hee Kim M, Davidson BL, et al. Transvascular delivery of small interfering rna to the central nervous system. Nature 2007; 448(7149): 39-43.
129. Gao K, Huang L. Nonviral methods for sirna delivery. Mol Pharm 2008; 6(3): 651-8.
130. Navarro G, Tros de Ilarduya C. Activated and non-activated pamam dendrimers for gene delivery in vitro and in vivo. Nanomed: Nanotechnol Biol Med 2009; 5(3): 287-97.
131. Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK, et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 2002; 62: 6831-6.
132. Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R, et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994; 269(4): 2550-61.
133. Mecke A, Majoros IJ, Patri AK, Baker Jr JR, Holl BMM, Orr BG. Lipid bilayer disruption by polycationic polymers: The roles of size and chemical functional group. Langmuir 2005; 21(23): 10348.
134. Chen J, Hessler JA, Putchakayala K, Panama BK, Khan DP, Hong S, et al. Cationic nanoparticles induce nanoscale disruption in living cell plasma membranes. J Phys Chem B 2009; 113(32): 11179-85.
135. Martina MS, Fortin JP, Fournier L, Menager C, Gazeau F, Clement O, et al. Magnetic targeting of rhodamine-labeled superparamagnetic liposomes to solid tumors: in vivo tracking by fibered confocal fluorescence microscopy. Mol Imaging 2007; 6(2): 140-6.
136. Goodman CM, McCusker CD, Yilmaz T, Rotello VM. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem 2004; 15(4): 897-900.
137. Herce H, Garcia A. Molecular dynamics simulations suggest a mechanism for translocation of the hiv-1 tat peptide across lipid membranes. Proc Natl Acad Sci USA 2007; 104: 20805-10.
138. Banks WA, Kastin AJ, Akerstrom V. Hiv-1 protein gp120 crosses the blood-brain barrier: Role of adsorptive endocytosis. Life Sci 1997; 61(9): PL119-PL25.
139. Weiss Clemens K, Kohnle M-V, Landfester K, Hauk T, Fischer D, Schmitz-Wienke J, et al. The first step into the brain: Uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation. Chem Med Chem 2008; 3(9): 1395-403.
140. Cotran RS. Endothelial phagocytosis: An electron-microscopic study. Exp Mol Pathol 1965; 4(2): 217-31.
141. Schoenberg MD, Gilman PA, Mumaw V, Moore RD. Proliferation of the reticuloendothelial system and phagocytosis. Exp Mol Pathol 1963; 2(2): 126-43.
142. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010; 10(5): 319-31.